Intelligent Polyethylene Glycol-Linker-Drug Conjugate Systems
Legal Citation
Summary of the Inventive Concept
The present disclosure relates to innovative systems integrating polyethylene glycol-linker-drug conjugates with cutting-edge technologies such as blockchain, artificial intelligence, Internet of Things, and machine learning to create more effective, personalized, and data-driven pharmaceutical solutions.
Background and Problem Solved
The original patent disclosed a polyethylene glycol-linker-drug conjugate with improved pharmaceutical properties. However, the conjugate's full potential was limited by the lack of integration with advanced technologies. The present inventive concept addresses this limitation by combining the conjugate with synergistic technologies to create a more powerful and efficient system.
Detailed Description of the Inventive Concept
The inventive concept comprises a polyethylene glycol-linker-drug conjugate integrated with blockchain-based data management platforms for secure and transparent tracking of the conjugate's distribution and usage. Additionally, the conjugate can be administered to patients and monitored using artificial intelligence-powered healthcare platforms, wearable devices, and Internet of Things networks. The system can also utilize machine learning algorithms to optimize the conjugate's efficacy and predict the optimal dosage and treatment schedule.
Novelty and Inventive Step
The novelty of the present inventive concept lies in the synergistic integration of the polyethylene glycol-linker-drug conjugate with advanced technologies, which provides a non-obvious solution to the limitations of the original patent. The inventive step is the recognition of the benefits of combining these technologies to create a more effective and efficient pharmaceutical system.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include integrating the conjugate with other advanced technologies such as robotics, augmented reality, or 3D printing. Variations of the system may also include different types of conjugates, data management platforms, or healthcare platforms.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of personalized medicine, disease treatment, and healthcare data management. The target market includes pharmaceutical companies, hospitals, and research institutions.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/60 |
| A | A61 | A61K31/704 |
| A | A61 | A61P35/00 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically drug delivery systems involving polyethylene glycol (PEG) conjugates, with expertise in chemical modification of therapeutic compounds and advanced drug delivery technologies
Person of Ordinary Skill (PHOSITA) Profile
A researcher or pharmaceutical scientist with advanced degree (PhD/MD) in pharmaceutical chemistry, biotechnology, or chemical engineering, having expertise in drug conjugation techniques, polymer chemistry, and familiarity with emerging medical technologies
Obviousness Rationale
A PHOSITA would recognize that integrating advanced digital technologies with existing drug conjugation platforms represents a predictable extension of pharmaceutical innovation. The core PEG-linker-drug conjugate structure remains fundamentally unchanged from the source patent, with the primary innovation being the addition of data management and monitoring technologies. These technological integrations would be considered routine optimization and implementation of known digital health strategies to enhance drug delivery and patient monitoring.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,635 |
|---|---|
| Title | Linker compound, polyethylene glycol-linker conjugate and derivative thereof and polyethylene glycol-linker-drug conjugate |
| Assignee(s) | JenKem Technology Co., Ltd. (Tianjin) |